Effects of zinc oxide nanoparticles on neural tube development in early chicken embryos

Fidan, Pinar Ayran; Efe, Ekin; Toprak, Uğur; Aynur, Julide; Hamsici, Yagmur; Coban, Beyza Nur; Canta, Sinem; Ozer, Reyyan Sena

doi:10.5137/1019-5149.jtn.42897-22.2

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, the end-effects of the pharmaceutical agent were evaluated rather than its acting mechanism on the development of the embryo or the neural tube. In this manner, the lack of further immunohistochemical analyses and/or genetic tests might be reported as a limitation, however, there are similar studies in the literature demonstrating only the drug effects on neural tube closure or embryonic development (Fidan et al, 2022;Guvenc et al, 2016;Kawakami et al, 2018;Mete et al, 2016;Ovalioglu et al, 2020;Secinti et al, 2021). Fourth, it would be attractive to examine rocuronium sugammadex complex or the latter with any general anesthetic, which might serve as a study object for future investigations.…”

Section: Facial Propertiesmentioning

confidence: 99%

The influence of different sugammadex doses on neural tube development in early‐stage chick embryos

Ayhan

Efe

Fidan

et al. 2023

Birth Defects Research

View full text Add to dashboard Cite

BackgroundSugammadex is a modified gamma‐cyclodextrin that has been developed with the goal of reversing the steroidal neuromuscular blocking agents. The aim of the present study is to investigate the effects of different sugammadex doses on embryologic and neural tube development in an early‐stage chick embryo model.MethodsA total of 100 specific pathogen‐free, fertilized domestic chicken eggs were randomly divided into five groups (n = 20, each), and placed in an automatic cycle incubator. The eggs in the “control (C)” group were incubated without administration of any drug till the end of the experiment. Sub‐blastodermic administration of 0.9% NaCl as vehicle control (VC) and different doses of sugammadex solutions prepared with the latter [2 mg/mL (LD), 4 mg/mL (MD), 16 mg/mL (HD)] were performed at 30 hr of incubation. All embryos were removed from the eggs at 72 hr when they were expected to reach Hamburger‐Hamilton (HH) stages 19–20, then they were fixed, and evaluated histo‐morphologically.ResultsEmbryonic development was not observed in 11 eggs (1 in C, 1 in VC; 3 in LD, 3 in MD, and 3 in HD). All the developed embryos were compatible with the HH stages 19–20. A neural tube closure defect was detected in one embryo in the HD group. No statistically significant difference was found between the groups in terms of embryonic and neural tube developments.ConclusionsNo significant association was found between the drug and adverse outcomes; however, a trend with dosing was seen. Further studies are required before conclude on safety and extrapolate these results to human beings.

show abstract